Floatz logo

Micardis®

Nonalcoholic Fatty Liver Disease (NAFLD)

Nanfang Hospital, Southern Medical UniversityPhase 4 / ApprovedDormant
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
95/ 100

Competitive context

140 Active assets in the Nonalcoholic Fatty Liver Disease (NAFLD) cohort.

Asset / SponsorPhaseRating
Dapagliflozin
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase 4BBB
Empagliflozin
Justin Ryder
Phase 4BBB
Exenatide
Fudan University
Phase 4BBB
Metformin
Xiqiao Zhou
Phase 4BBB
Pioglitazone
Badr University
Phase 4BBB

View all 50 →

Same molecule, other indications

Micardis® is also rated in:

hypertensive disorderDormant
BB
Indicative ·
71 / 100
View asset →
abdominal obesity-metabolic syndromeDormant
BB
Indicative ·
70 / 100
View asset →
schizoaffective disorderDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →